July 4, 2018
The David Forbes-Nixon Charitable Foundation (DFN Charitable Foundation) is delighted to announce the appointment of Dr Martin Kaiser as the inaugural Jacquelin Forbes-Nixon Research Fellow.
Dr Kaiser, who heads up the Myeloma UK Translational Myeloma Research Centre at The Institute of Cancer Research, London, will be taking up the post from 2 July 2018.
Under the Fellowship, Dr Kaiser will undertake a programme of work to identify and characterise the genetic changes responsible for the progression of myeloma and why it becomes resistant to treatment. The project will be based on 2,000 bone marrow samples from patients recruited to the Myeloma XI trial and Myeloma UK Clinical Trial Network which have been banked at The Institute of Cancer Research (ICR).
Speaking about his appointment, Dr Kaiser said: “Being appointed as the inaugural Jacquelin Forbes-Nixon Research Fellow is a tremendous honour. I am very grateful to David Forbes-Nixon and the trustees of the Foundation for this incredible opportunity.’’
It is hoped results from this research will help researchers design effective treatment combinations and regimens with the ability to overcome treatment resistance, improving both survival and quality of life of myeloma patients.
One of the major objectives of the DFN Charitable Foundation is funding research to find a cure for myeloma, and the establishment of this Fellowship marks a significant milestone in working towards achieving this goal.
Speaking about the appointment, David Forbes Nixon, Founder and Chairman of the Foundation said:
“My mother was the light of my life and I was heart-broken when she died of this terrible disease over 10 years ago at a young age. My Foundation is determined to help find a cure for myeloma by working with the brightest and the best in this field and I am delighted that Dr Kaiser has become the first Jacquelin Forbes-Nixon Research Fellow at the ICR. I wish him every success in this important role.”
Prof Paul Workman, Chief Executive and President of The Institute of Cancer Research, London, added:
“I am very proud that Dr Martin Kaiser has been appointed as the first Jacquelin Forbes-Nixon Research Fellow. Myeloma is a complex and challenging disease, but there is so much potential to change the treatment landscape through better understanding of its genetics and biology and the ICR provides a superb research environment to achieve this.”
The appointment of Dr Kaiser to the Fellowship follows a £1 million donation from the David Forbes-Nixon Charitable Foundation in May 2017 to Myeloma UK. The Fellowship complements Myeloma UK’s strategic investments in genomics research and precision medicine at the ICR.
Simon Ridley, Director of Research at Myeloma UK said:
“We are extremely excited by the potential of Dr Kaiser’s new myeloma research to help improve our understanding of this complex disease. The generous £1m donation from the David Forbes-Nixon Charitable Foundation will help ensure that Myeloma UK can carry on with our vital work to Make Myeloma History”.